Max Lycke
Overview
Explore the profile of Max Lycke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mygland L, Brinch S, Strand M, Olsen P, Aizenshtadt A, Lund K, et al.
iScience
. 2021 Aug;
24(7):102807.
PMID: 34337362
Small-molecule tankyrase 1 and tankyrase 2 (TNKS1/2) inhibitors are effective antitumor agents in selected tumor cell lines and mouse models. Here, we characterized the response signatures and the in-depth mechanisms...
2.
Waaler J, Leenders R, Sowa S, Brinch S, Lycke M, Nieczypor P, et al.
J Med Chem
. 2020 Jun;
63(13):6834-6846.
PMID: 32511917
Tankyrases 1 and 2 are central biotargets in the WNT/β-catenin signaling and Hippo signaling pathways. We have previously developed tankyrase inhibitors bearing a 1,2,4-triazole moiety and binding predominantly to the...
3.
Waaler J, Mygland L, Tveita A, Strand M, Solberg N, Olsen P, et al.
Commun Biol
. 2020 Apr;
3(1):196.
PMID: 32332858
The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy. Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade. Evidence for WNT/β-catenin signaling-mediated...
4.
Siller R, Dufour E, Lycke M, Wilmut I, Jung Y, Park I, et al.
Int J Pharm
. 2017 Mar;
522(1-2):1-10.
PMID: 28254654
A challenge to protein based therapies is the ability to produce biologically active proteins and their ensured delivery. Various approaches have been utilised including fusion of protein transduction domains with...
5.
Siller R, Naumovska E, Mathapati S, Lycke M, Greenhough S, Sullivan G
Sci Rep
. 2016 Nov;
6:37178.
PMID: 27872482
A challenge facing the human pluripotent stem cell (hPSC) field is the variability observed in differentiation potential of hPSCs. Variability can lead to time consuming and costly optimisation to yield...
6.
Mathapati S, Siller R, Impellizzeri A, Lycke M, Vegheim K, Almaas R, et al.
Curr Protoc Stem Cell Biol
. 2016 Aug;
38:1G.6.1-1G.6.18.
PMID: 27532814
Hepatocyte-like cells (HLCs) generated in vitro from human pluripotent stem cells (hPSCs) provide an invaluable resource for basic research, regenerative medicine, drug screening, toxicology, and modeling of liver disease and...